2
Orphan Designations
0 approved, 2 designated
0
FDA Approvals
2
Active Trials
200 recruiting
4
Rare Diseases
across 9 areas
0
News (30d)
Quiet
DualityBio Inc. is a company with 2 orphan drug designations across 4 rare diseases. Active clinical trials in 2 indications.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| esophageal cancer | humanized anti-B7 homologue monoclonal antibody covalently linked to topoisomerase I inhibitor | Des.TrialAppr. |
| lupus erythematosus | - | Des.TrialAppr. |
| ovarian cancer | - | Des.TrialAppr. |
| small cell lung carcinoma | Antibody-drug conjugate composed of an anti-B7-H3 IgG1 monoclonal antibody covalently linked to a topoisomerase I inhibitor (P1021) | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
32
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
32
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio